Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  decitabine
Find trials that include:  Any drugs shown
Results 1-25 of 34 for your search:
Start Over
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN33A-005, NCI-2016-00878, 2015-003482-28, NCT02785900
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGI-110-06, NCI-2017-00040, NCT02920008
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703, NCT02085408
Dasatinib and Decitabine in Treating Patients with Accelerated or Blastic Phase Chronic Myelogenous Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0333, NCI-2012-00014, CA180357, NCT01498445
Decitabine, Vemurafenib, and Cobimetinib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, MPD-RC 107, GCO 13-1816, NCT02076191
Ruxolitinib Phosphate and Decitabine in Treating Patients with Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0344, NCI-2014-02299, NCT02257138
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-339-1559, NCI-2016-00088, NCT02343939
Decitabine and Talazoparib in Treating Patients with Untreated Relapsed, or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1565GCC, NCI-2017-00417, NCT02878785
Cladribine, Cytarabine, and Decitabine in Treating Patients with Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2011-0987, NCI-2012-00145, NCT01515527
Genomic Predictors of Decitabine Response in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201210102, NCI-2012-01576, NCT01687400
Different Schedules of Decitabine in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: 2012-1017, NCI-2013-00463, NCT01786343
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Midostaurin and Decitabine in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: MC1483, NCI-2015-02107, NCT02634827
A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1315.2, NCI-2016-01034, 2015-002892-30, NCT02632721
Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 65 to 74
Trial IDs: ICT8, NCI-2016-01186, NCT02802267
Decitabine and Tetrahydrouridine in Treating Patients with Refractory and Relapsed T- or B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE1416, NCI-2016-01902, NCT02846935
Pembrolizumab, Decitabine, and Standard Chemotherapy before Surgery in Treating Patients with Locally Advanced HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-15-11083, NCI-2016-01980, NCT02957968
Decitabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201703089, NCI-2017-00497, NCT03063203
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
Pacritinib and Chemotherapy in Treating Patients with Acute Myeloid Leukemia and FLT3 Mutations
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14169, NCI-2014-02436, NCT02323607
Ipilimumab and Decitabine in Treating Patients with Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10026, NCI-2016-01326, NCT02890329
Start Over